Oncology Archives - CureVac

Intratumoral RNA-based TLR-7/-8 and RIG-I Agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy

Immunological effects of a novel RNA-based adjuvant in liver cancer patients

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors